Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML).
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-016 | Anti-Human CD20 Recombinant Antibody (Rituximab) | IF, IP, Neut, FuncS, ELISA, FC, WB | IgG1 - kappa |
TAB-207 | Anti-Human CD20 Recombinant Antibody | ELISA, IP, FC, FuncS, Neut, IF, ICC | IgG1 - kappa |
TAB-1692CL-F(E) | Anti-Human MS4A1 Recombinant Antibody Fab Fragment (Zytux) | ELISA, WB | Chimeric antibody (mouse/human) |
TAB-1700CL-F(E) | Anti-Human MS4A1 Recombinant Antibody Fab Fragment (R92-3-1) | ADCC | Chimeric antibody (mouse/human) |
PABX-026 | Recombinant Human Anti-CD20 Antibody (C2H7) | FuncS | IgG |
There are currently no Customer reviews or questions for Gly-003CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.